UBS Group »

Carmell Therapeutics Corp - US shares owned by UBS Group

Quarter-by-quarter ownership of Carmell Therapeutics Corp - US (CTCX) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Carmell Therapeutics Corp - US

Tip: Access up to 7 years of quarterly data

All positions including Carmell Therapeutics Corp - US held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Carmell Therapeutics Corp - US by UBS Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.6k 690 3.81

More positions owned by UBS Group

Microsoft Corporation (MSFT)
Apple Call Option (AAPL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
NVIDIA Corporation (NVDA)
Ubs Group SHS (UBS)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Union Pacific Corporation (UNP)
Alphabet Cap Stk Cl C Put Option (GOOG)
Meta Platforms Cl A (META)

View all positions for UBS Group

Top funds holding Carmell Therapeutics Corp - US

Vanguard Group
Carnegie Mellon University
Citadel Advisors
Hubbell Strickland Wealth Management
UBS Group
Wells Fargo & Company
Royal Bank of Canada
Bank of America Corporation
Jpmorgan Chase & Co

View all funds holding Carmell Therapeutics Corp - US